Sanofi (NASDAQ:SNY) is one of the best undervalued stocks under $50 to invest in now. Sanofi (NASDAQ:SNY) announced on March ...
Add Yahoo as a preferred source to see more of our stories on Google. For men facing the return of prostate cancer, a new combination therapy may offer a much longer break before the disease comes ...
FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tractMeiraGTx to hold ...
NEWARK, CA / ACCESS Newswire / August 25, 2025 / Protagonist Therapeutics, Inc. (PTGX) ("Protagonist" or "the Company") announced today that rusfertide, a potential first-in-class hepcidin-mimetic ...
The U.S. Food and Drug Administration has granted breakthrough therapy designation to Sanofi’s (SNY) venglustat, a novel, ...
Add Yahoo as a preferred source to see more of our stories on Google. The latest FDA recognition is supported by positive results from several studies Novartis has announced that the US Food and Drug ...
Incyte INCY announced that the FDA has granted the Breakthrough Therapy designation to its investigational, first-in-class, mutCALR-targeted monoclonal antibody, INCA033989, to treat patients with ...
Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Rilzabrutinib is the first and only investigational BTKi ...
Eli Lilly and Company LLY announced that the FDA has granted a Breakthrough Therapy designation to its novel folate receptor alpha (FRα) antibody-drug conjugate (ADC), sofetabart mipitecan (LY4170156) ...
-- Breakthrough Therapy Designation Based on Positive RECONNECT Phase 2 Clinical Data -- -- Aligned with U.S. Food and Drug Administration on Registrational Path for Luvesilocin in Postpartum ...
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results